Anya Biopharm Inc. (TPEX:7776)
Taiwan · Delayed Price · Currency is TWD 32.35
+1.45 (4.69%)
At close: Sep 2, 2026
Anya Biopharm Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 158.33 | 150.75 | 290.22 | 11.46 | 2.07 |
Short-Term Investments | 158.97 | 219.47 | 163.93 | - | - |
Cash & Short-Term Investments | 317.3 | 370.22 | 454.15 | 11.46 | 2.07 |
Cash Growth | -17.91% | -18.48% | 3864.28% | 454.50% | - |
Accounts Receivable | 0.12 | 11.88 | 3.4 | 0.17 | 0.56 |
Other Receivables | 4.32 | 5.02 | 2.8 | - | 0.75 |
Receivables | 4.45 | 16.9 | 6.2 | 0.17 | 1.31 |
Prepaid Expenses | 12.91 | 4.61 | 0.85 | - | 1.46 |
Other Current Assets | 0.76 | 0.97 | 0.68 | 1.41 | 0.76 |
Total Current Assets | 335.41 | 392.7 | 461.88 | 13.03 | 5.6 |
Property, Plant & Equipment | 8.77 | 8.74 | 9.15 | 1.72 | 2.5 |
Other Intangible Assets | 5.75 | 5.99 | 5.08 | 5.08 | 0.6 |
Other Long-Term Assets | 7.44 | 6.46 | 5.22 | 2.4 | 2.86 |
Total Assets | 357.49 | 413.87 | 481.32 | 22.23 | 11.56 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accrued Expenses | 3.68 | 6.99 | 6.47 | 1.85 | 1.38 |
Short-Term Debt | - | - | - | 102.01 | 63.28 |
Current Portion of Leases | 0.35 | 0.12 | 0.17 | 0.95 | 0.82 |
Current Unearned Revenue | - | - | 3.23 | - | - |
Other Current Liabilities | 0.54 | 1.08 | 1.24 | 0.61 | 0.36 |
Total Current Liabilities | 4.96 | 8.19 | 11.11 | 105.41 | 65.84 |
Long-Term Leases | 3.17 | 2.83 | 3.25 | 0.08 | 0.9 |
Total Liabilities | 8.13 | 11.02 | 14.36 | 105.49 | 66.74 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 491.02 | 491.02 | 491.02 | 8.77 | 8.77 |
Additional Paid-In Capital | 14.82 | 14.82 | 14.82 | 16.38 | 16.38 |
Retained Earnings | -156.26 | -102.85 | -38.83 | -108.39 | -80.31 |
Comprehensive Income & Other | -0.24 | -0.16 | -0.13 | -0.04 | -0.04 |
Total Common Equity | 349.34 | 402.83 | 466.89 | -83.28 | -55.19 |
Minority Interest | 0.02 | 0.02 | 0.08 | 0.01 | 0.02 |
Shareholders' Equity | 349.36 | 402.85 | 466.97 | -83.26 | -55.18 |
Total Liabilities & Equity | 357.49 | 413.87 | 481.32 | 22.23 | 11.56 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 3.52 | 2.96 | 3.41 | 103.03 | 65 |
Net Cash (Debt) | 313.78 | 367.26 | 450.73 | -91.58 | -62.93 |
Net Cash Growth | -18.20% | -18.52% | - | - | - |
Net Cash Per Share | 6.39 | 7.48 | 13.62 | -40.16 | -27.60 |
Filing Date Shares Outstanding | 49.1 | 49.1 | 49.1 | 8.77 | 2.28 |
Total Common Shares Outstanding | 49.1 | 49.1 | 49.1 | 8.77 | 2.28 |
Working Capital | 330.45 | 384.51 | 450.77 | -92.39 | -60.24 |
Book Value Per Share | 7.11 | 8.20 | 9.51 | -9.50 | -24.21 |
Tangible Book Value | 343.59 | 396.84 | 461.8 | -88.36 | -55.79 |
Tangible Book Value Per Share | 7.00 | 8.08 | 9.41 | -10.07 | -24.47 |
Machinery | 4.31 | 4.18 | 2.69 | 1 | 0.94 |
Leasehold Improvements | 3.33 | 3.46 | 3.8 | - | - |